Af­ter a bad quar­ter, Il­lu­mi­na fo­cus­es on new DNA se­quenc­ing plat­form

3 years ago
Pharma

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

3 years ago
Pharma
In Focus

The drug pric­ing pres­i­dent: Biden warns of ve­to for any IRA re­peal at­tempts

3 years ago
Law

Swiss rare dis­ease biotech with­draws IPO to up­date its Nas­daq plans

3 years ago
Financing

As clin­i­cal tri­als get more com­plex, soft­ware start­up Faro bags $20M to help vi­su­al­ize them

3 years ago
Financing
Startups

A small change in your in­box each morn­ing

3 years ago
Editor's note

FDA as­sem­bles ad­comm to re­view GSK's Jem­per­li tri­al plans in rec­tal can­cer

3 years ago
R&D
FDA+

Re­searchers pan phar­ma DTC ad­ver­tis­ing for high spend­ing on low-val­ue drugs — JA­MA re­port

3 years ago
Pharma
Marketing

#JPM23: This is how we cure can­cer

3 years ago

Biden to tout phar­ma's de­feat in State of the Union, call for $35 in­sulin for all

3 years ago
FDA+
Law

Pfiz­er or­dered to dis­close FBI com­mu­ni­ca­tions in trade se­crets case

3 years ago
Pharma
Law

Pa­tients, ad­vo­ca­cy groups launch fight against Trikaf­ta patents in four coun­tries

3 years ago
Pharma

Chat­G­PT and gen­er­a­tive AI land in phar­ma mar­ket­ing with sense of awe — and plen­ty of cau­tion

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er plans mar­ket­ing spend bump for 2023; Am­gen, Mer­ck join ‘Project Black’ eq­ui­ty fund­ing

3 years ago
Pharma
Marketing

Aus­tralian biotech touts a pos­i­tive mid-stage da­ta read­out — with old Shire drug

3 years ago
R&D

As ac­qui­si­tion ru­mors sur­face, Catal­ent re­mains mum on deal

3 years ago
Deals
Manufacturing

Aldeyra’s sights set on No­vem­ber PDU­FA; Syn­bio start­up scores cash

3 years ago
News Briefing

A tech­ni­cal­i­ty could keep RSV shots from kids in need

3 years ago
R&D

Blood stem cell ther­a­py mak­er Garu­da nabs $62M

3 years ago
Financing
Startups

Roche says its C5 in­hibitor aced PhI­II head-to-head tri­als with As­traZeneca’s Soliris

3 years ago
R&D

On­colyt­ic virus start­up TILT rais­es €22M to ad­vance can­cer ther­a­pies

3 years ago
Financing

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — ...

3 years ago
Deals
Bioregnum

Dana­her ap­proached con­tract man­u­fac­tur­er Catal­ent about ac­qui­si­tion – re­port

3 years ago
Deals
Manufacturing

DC ap­peals court re­vives case ac­cus­ing phar­mas of fi­nanc­ing ter­ror at­tacks

3 years ago
Pharma
Law
First page Previous page 379380381382383384385 Next page Last page
A service from the Financial Times